APA (7th ed.) Citation

R, B., F, A., BD, E., A, A. H., S, S., B, Y., . . . CG, B. (2026). Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, Double-Blind, Phase 3 Trials. American journal of clinical dermatology, 27(1), 199. https://doi.org/10.1007/s40257-025-00974-4

Chicago Style (17th ed.) Citation

R, Bissonnette, Albreiki F, Ehst BD, Al Hammadi A, Schliemann S, Yang B, Zhang J, and Bunick CG. "Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, Double-Blind, Phase 3 Trials." American Journal of Clinical Dermatology 27, no. 1 (2026): 199. https://doi.org/10.1007/s40257-025-00974-4.

MLA (9th ed.) Citation

R, Bissonnette, et al. "Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, Double-Blind, Phase 3 Trials." American Journal of Clinical Dermatology, vol. 27, no. 1, 2026, p. 199, https://doi.org/10.1007/s40257-025-00974-4.